2019 highlights: ENPICOM’s year in review

A look back at some of the year’s biggest milestones

January 16, 2020

The new decade is already upon us. That means there is no better time to look back on our immunomics highlights of last year. We are incredibly proud of 2019 and all that was accomplished. We launched new products, entered into new strategic partnerships, and got recognized as one of the most promising startups in Europe.

Delivering unique immune repertoire data handling solutions 

 

ENPICOM brought a unique software solution to the market – the ImmunoGenomiX (IGX) Platform. Its robust data handling features allows life scientists and biopharma companies to discover valuable insights to improve the health of patients treated with immunotherapy or affected by immune system related diseases or conditions. As the development of the platform continues, we are adding more features and enhancements to it. The latest version (1.1) offers several speed improvements as well as a new quality assurance app (IGX-Inspect).

IGX-Inspect app

Learn more about the IGX Platform here.

Offering full IGX services to accelerate immunotherapy discovery and development

 

To deliver complete immune repertoire sequencing and data analysis services, we joined forces with DDL Diagnostic Laboratory. Now we can support organizations that don’t have the necessary expertise or capabilities in-house. Our full-service proposition includes sample preparation, sequencing, data analysis, and visualization. Besides, all of our service customers get 48-hour complimentary access to our SaaS platform which allows them to experience its extraordinary data mining power themselves.

Visit this page to learn more about our IGX services.

Accelerating innovation through strategic partnerships

 

BOM Brabant Ventures, NextGen Ventures, and Arches Capital jointly strengthened our ambition to become a global player in the field of immunomics. The investors’ support allowed us to finalize the IGX Platform development.

Moreover, we have established a fruitful collaboration with Cytura Therapeutics to develop a new biomarker for early cancer detection and received a joint MIT-Zuid R&D partnership subsidy.

Supporting scientific research

 

Our team had the honor to work together with some of the brightest minds in the biomedical field and contributed to the publication of the following scientific papers:

 

On top of that, we had the chance to attend several relevant events to connect with researchers in the market and share our knowledge. Make sure to check out the recordings of the presentations our team gave at Genomics live, World Vaccine Congress, and European Antibody Discovery Congress.

Scientific papers ENPICOM team contributed to

Visit our knowledge center for more online resources.

Getting the right people on the bus

 

In the past year, the ENPICOM team has doubled in size, growing from 10 to 20 employees, and we opened a satellite office in Amsterdam. We have built a top-class, diverse team of experts with the right combination of knowledge and expertise to jointly tackle the data analysis and software engineering challenges related to the field of immunomics.

Together with our scientific and strategic partners and supported by our investors, we develop tools and validate applications to truly bridge the gap between immune repertoire sequencing and the insights needed to improve human health.

ENPICOM team
Meet our team.

Looking ahead

 

We want to thank you all for your continued support and partnership. We are excited to enter 2020 together and keep innovating with software products that help you advance your research, facilitate faster drug development, and eventually improve health outcomes for everyone.

Subscribe to the ENPICOM newsletter to get the latest news and content in 2020!